PT3056492T - Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) - Google Patents

Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)

Info

Publication number
PT3056492T
PT3056492T PT151993557T PT15199355T PT3056492T PT 3056492 T PT3056492 T PT 3056492T PT 151993557 T PT151993557 T PT 151993557T PT 15199355 T PT15199355 T PT 15199355T PT 3056492 T PT3056492 T PT 3056492T
Authority
PT
Portugal
Prior art keywords
megumine
delafloxacin
drug
salt
crystalline forms
Prior art date
Application number
PT151993557T
Other languages
English (en)
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PT3056492T publication Critical patent/PT3056492T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/18Polyhydroxylic acyclic alcohols
    • C07C31/26Hexahydroxylic alcohols

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT151993557T 2004-10-08 2005-10-07 Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) PT3056492T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61733404P 2004-10-08 2004-10-08

Publications (1)

Publication Number Publication Date
PT3056492T true PT3056492T (pt) 2021-12-27

Family

ID=36129950

Family Applications (1)

Application Number Title Priority Date Filing Date
PT151993557T PT3056492T (pt) 2004-10-08 2005-10-07 Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)

Country Status (13)

Country Link
US (8) US7728143B2 (pt)
EP (3) EP1802607A2 (pt)
CA (1) CA2582954C (pt)
CY (1) CY1125048T1 (pt)
DK (1) DK3056492T3 (pt)
ES (1) ES2901955T3 (pt)
HU (1) HUE056718T2 (pt)
LT (1) LT3056492T (pt)
MX (1) MX2007004111A (pt)
PL (1) PL3056492T3 (pt)
PT (1) PT3056492T (pt)
SI (1) SI3056492T1 (pt)
WO (1) WO2006042034A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
DK3056492T3 (da) * 2004-10-08 2021-12-13 Abbvie Inc Megluminsalt og krystallinke former deraf af et lægemiddel (delafloxacin)
ES2384333T3 (es) * 2005-04-11 2012-07-03 Abbott Laboratories Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles
PL3766876T3 (pl) 2008-09-24 2024-04-02 Melinta Subsidiary Corp. Preparat farmaceutyczny zawierający pochodną chinolonu
AU2009314072C1 (en) * 2008-11-15 2016-11-10 Melinta Subsidiary Corp. Antimicrobial compositions
CA2903755A1 (en) * 2013-03-08 2014-09-12 Melinta Therapeutics, Inc. Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate
KR102237887B1 (ko) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
TWI705814B (zh) * 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
CN107205989A (zh) 2014-11-14 2017-09-26 梅琳塔治疗公司 治疗、预防或降低皮肤感染风险的方法
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
CN106256824B (zh) * 2015-06-18 2020-10-27 重庆医药工业研究院有限责任公司 一种高纯度德拉沙星葡甲胺盐的制备方法
CN105017223B (zh) * 2015-07-08 2017-08-01 扬子江药业集团有限公司 德拉沙星葡甲胺晶型i及其制备方法
CN105017224A (zh) * 2015-07-10 2015-11-04 扬子江药业集团有限公司 一种德拉沙星葡甲胺晶型的制备方法
CN106916142A (zh) * 2015-12-25 2017-07-04 江苏奥赛康药业股份有限公司 一种制备高纯度德拉沙星的方法
CN111718331A (zh) * 2019-03-23 2020-09-29 南京海润医药有限公司 德拉沙星的杂质i和ii及产品精制方法
CN111718330A (zh) * 2019-03-23 2020-09-29 南京海润医药有限公司 一种德拉沙星杂质iii及产品精制方法
CN111718329A (zh) * 2019-03-23 2020-09-29 南京海润医药有限公司 一种德拉沙星杂质iv及产品精制方法
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
CN116514775B (zh) * 2022-01-20 2024-11-29 安徽普利药业有限公司 一种徳拉沙星葡甲胺盐新晶型及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
JPH09511516A (ja) 1994-04-12 1997-11-18 カイロサイエンス・リミテッド グルカミン誘導体を用いるエトドラックの分割法
DK0992501T3 (da) * 1995-09-22 2002-10-28 Wakunaga Pharma Co Ltd Pyridoncarboxylsyre derivater som antibakterielle midler
EP0945134A1 (de) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
CZ20022413A3 (cs) 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
JP4337283B2 (ja) 2001-07-11 2009-09-30 ソニー株式会社 光ピックアップ装置及び記録及び/又は再生装置
JP4290381B2 (ja) 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 ピリドンカルボン酸化合物含有エマルション
JP2004168772A (ja) 2002-11-06 2004-06-17 Takeda Chem Ind Ltd 受容体調節剤
DK3056492T3 (da) * 2004-10-08 2021-12-13 Abbvie Inc Megluminsalt og krystallinke former deraf af et lægemiddel (delafloxacin)

Also Published As

Publication number Publication date
PL3056492T3 (pl) 2022-03-21
US9873681B2 (en) 2018-01-23
DK3056492T3 (da) 2021-12-13
US20140155380A1 (en) 2014-06-05
US20170073329A1 (en) 2017-03-16
US10329276B2 (en) 2019-06-25
WO2006042034A3 (en) 2006-06-22
EP3957632A1 (en) 2022-02-23
CA2582954C (en) 2014-07-29
HUE056718T2 (hu) 2022-03-28
EP3056492B1 (en) 2021-09-22
US20150196547A1 (en) 2015-07-16
US20070043019A1 (en) 2007-02-22
US20100261703A1 (en) 2010-10-14
EP3056492A1 (en) 2016-08-17
ES2901955T3 (es) 2022-03-24
LT3056492T (lt) 2022-01-25
WO2006042034A2 (en) 2006-04-20
JP2008515910A (ja) 2008-05-15
US9539250B2 (en) 2017-01-10
US8969569B2 (en) 2015-03-03
US20180105510A1 (en) 2018-04-19
WO2006042034A8 (en) 2007-09-07
US7728143B2 (en) 2010-06-01
MX2007004111A (es) 2007-06-14
US20130060040A1 (en) 2013-03-07
US8648093B2 (en) 2014-02-11
CY1125048T1 (el) 2023-06-09
US8273892B2 (en) 2012-09-25
JP5294633B2 (ja) 2013-09-18
SI3056492T1 (sl) 2022-03-31
CA2582954A1 (en) 2006-04-20
EP1802607A2 (en) 2007-07-04
US8252813B2 (en) 2012-08-28
US20100286397A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
PT3056492T (pt) Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
HUS000502I2 (hu) Opikapon vagy egy gyógyászatilag elfogadható sója
SI1789021T1 (sl) Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol
LT3281939T (lt) Derinys, apimantis stabilų 4-oksochinolino junginio kristalą
PT1802579E (pt) Derivados da 3-arilaminopiridina
AP2006003768A0 (en) TetraazabenzoÄeÜazulene derivatives and analogs tehereof
ZA200708327B (en) Reduction of postoperative pain medication
PL1846566T3 (pl) Stabilne kryształy natamycyny o kształcie igiełkowatym
PL370481A1 (en) Salts of valsartan
EP1614719A4 (en) AZOVER BINDING AND SALT THEREOF
ZA200609205B (en) Crystalline forms of duloxetine free base
IL176141A0 (en) Crystalline forms of valacyclovir hydrochloride
EP1773339A4 (en) CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
EP1758664A4 (en) PROCESS USING CONTROLLED CRYSTALLIZATION TO FORM CRYSTALS OF A PHARMACEUTICAL PRODUCT
PL1802329T3 (pl) Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę
PT1631575E (pt) NOVOS DERIVADOS 3- DECLADINOSIL 9ª-N-CARBAMOIL E 9ª-N- TIOCARBAMOIL DE 9-DESOXI-9-DI-HIDRO-9ª-AZA-9ª-HOMOERITROMICINA
EP1885381A4 (en) PHARMACEUTICAL USE OF GRAPTOPETALUM AND RELATED PLANTS
ZA200608305B (en) Pharmaceutical composition comprising a salt of mirtazapine
PL1705998T3 (pl) Zastosowanie karboksypeptydazy
EP1744742A4 (en) CRYSTALLINE FORMS AND AMORPHOUS SODIUM EFAPROXIRAL
IL177451A0 (en) Crystalline forms of a pharmaceutical compound
SI1592417T1 (sl) Kombinacija zdravil proti diabetesu
PL373776A1 (en) Oral pharmaceutical compound
GB2406659B (en) Medical clock